Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet function of prasugrel vs clopidogrel in stable coronary artery disease assessed by light transmission aggregometry
jRCT1031220254Not yet recruiting
- Sponsor
- Isoda Kikuo
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of prasugrel, clopidogrel and aspirin in coronary arteriosclerosis (2 arms), sponsored by Isoda Kikuo. Primary endpoint: Platelet agglutination ability (NSR-2). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
prasugrelclopidogrelaspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT1031220254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220254.